BridgeMD
Effect of H2 inhalation therapy on early recurrence after atrial fibrillation ablation.
EU CTIS ID: 2024-520131-33-00
What this study is testing
To study the efficacy of inhaled hydrogen therapy on early recurrence of atrial fibrillation after ablation and improvement of quality of life at 3 months.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Be over 18 years of age
- Have paroxysmal or persistent AF with symptoms lasting less than 6 months
- Be a candidate for first-time AF ablation (cryoablation, electroporation)
- Understand and agree to comply with the study procedures
- Have a smartphone
- Be enrolled in a social security program or have similar rights
You likely can't join if
- Be over 80 years of age
- Persons referred to in Articles L1121-5 to L1121-8 of the CSP and Articles 31 to 35 of Regulation 536/2014 (corresponds to all protected persons: pregnant women, women in labor, breastfeeding mothers, persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, persons admitted to a health or social care institution for purposes other than research, minors, persons subject to legal protection measures or unable to give their consent).
- Personnel with a hierarchical relationship with the principal investigator
- Have a left atrial diameter ≥ 50 mm on TEE.
- Have a history of AF ablation.
- Radiofrequency ablation.
See the full eligibility criteria
- Be over 18 years of age
- Have paroxysmal or persistent AF with symptoms lasting less than 6 months
- Be a candidate for first-time AF ablation (cryoablation, electroporation)
- Understand and agree to comply with the study procedures
- Have a smartphone
- Be enrolled in a social security program or have similar rights
- Have signed the study consent form
- Be over 80 years of age
- Persons referred to in Articles L1121-5 to L1121-8 of the CSP and Articles 31 to 35 of Regulation 536/2014 (corresponds to all protected persons: pregnant women, women in labor, breastfeeding mothers, persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, persons admitted to a health or social care institution for purposes other than research, minors, persons subject to legal protection measures or unable to give their consent).
- Personnel with a hierarchical relationship with the principal investigator
- Have a left atrial diameter ≥ 50 mm on TEE.
- Have a history of AF ablation.
- Radiofrequency ablation.
- Patient undergoing long-term anti-inflammatory treatment.
- Patients with gas administration equipment (CPAP, NIV, etc.)
- Women of childbearing potential
- Uncooperative patients
- During exclusion period from another study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.